A Bioequivalence Study to Compare and Evaluate the Pharmacokinetic Characteristics and the Safety After Administration of DW5221 and DW5221-R in Healthy Adult Male Volunteers
Latest Information Update: 01 Dec 2023
At a glance
- Drugs DW-5221 (Primary)
- Indications Eating disorders
- Focus Pharmacokinetics
- Sponsors Daewon Pharmaceutical
Most Recent Events
- 01 Dec 2023 New trial record